Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Next Hurdles For COVID-19 Vaccine Development: Selecting Endpoints, Getting Enough Subjects

Executive Summary

US FDA's Peter Marks and industry execs discuss challenges in moving candidate vaccines to Phase II/III trials, including international regulatory alignment on clinical endpoints and other issues. J&J's Paul Stoffels says it is going to be a 'Herculean task' to conduct placebo-controlled studies in 30,000 to 100,000 people.

You may also be interested in...



ACTIV Picks Potential COVID-19 Therapeutics To Be Tested In Master Protocol Trials

Three host-targeted immune modulators, three anticoagulants, and three to six neutralizing antibodies are to be tested in ACTIV clinical trials, FNIH's David Wholley tells DIA meeting.

US FDA Looking To Real-World Evidence To Fill in Gaps On COVID-19 Vaccines

Principal Deputy Commissioner Amy Abernethy suggests FDA may clear a COVID-19 vaccine on smaller than usual clinical datasets and rely on real-world data to fill in the gaps. Abernethy said a new public-private partnership is starting to explore how it can use real-world data and evidence for COVID-19 vaccine evaluation.

COVID-19: The Race To Develop A Vaccine

The world is waiting for a coronavirus vaccine – but can we depend on it, and when will it arrive? A visual tracker of key developments from leading candidates.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel